Status: Recruiting
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
Participants needed: 61
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Anbogen Therapeutics, Inc.Updated: Jun 24, 2024Locations: 5
Eligibility criteria
Male or female aged ≥ 20 years or adult age as per local regulations, at time of... [+5]
Known active or untreated central nervous system (CNS) metastases and/or carcino... [+10]